AYTU news

Latest 1 stories · newest Sep 22, 2026

AYTU

Aytu BioPharma Reports Fiscal 2026 Financial Results

Aytu BioPharma reported a 6.4% increase in Q4 net revenue to $16.1 million, driven by the ADDVANCE gel product. The company highlighted the commercial launch of its EXXUA product, recording revenue of $6.6 million for the fiscal year.

Earnings Sep 22, 2026 sentiment +0.10 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same AYTU feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/AYTU/newsSTART FREE